"The number one advantage regarding Nevisense is that it backs up my decision and provides me with more certainty in whether or not to excise a lesion"Dr. Isabel Gahlen, Ludwigsburg, Germany
Letter from the CEO, SciBase April 2019April 17, 2019
Dear SciBase shareholders,
New study opens up new applications for SciBase’s product Nevisense
SciBase announces skin barrier testing collaboration with leading Swiss research centerDecember 6, 2018
Clinical Guideline for Nevisense published in GermanyNovember 19, 2018
The following people have been appointed as members of SciBase Holding’s election committee for the Annual General Meeting in 2019:November 5, 2018
New US Study: Nevisense shows significant positive impact on clinical decision makingNovember 2, 2018
SciBase releases major improvements to NevisenseJune 21, 2018
The previously announced breakthrough update to Nevisense, SciBase device for the early detection of melanoma, has now been released.
Improved accuracy and usability for SciBase Nevisense can create a larger marketMay 22, 2018
Bulletin from annual general meeting of SciBase Holding AB (publ) on 16 May 2018May 16, 2018
At the annual general meeting of SciBase Holding AB (publ) on 16 May 2018 in Stockholm the shareholders adopted the below resolutions.
- Load more news...